News Ironwood crashes down as FDA seeks new phase 3 trial Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.
News Ironwood felled by mixed data in short bowel syndrome trial Ironwood Pharma has issued an upbeat assessment of phase 3 trial data with apraglutide for short bowel syndrome (SBS), but missed secondary outcome measures led to a sharp
News Positive phase 3 results for Zealand Pharma's glepaglutide Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the